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Three Popular Medicinal Mushroom Supplements:
A Review of Human Clinical Trials
Megan Frost, M.Ed., MLS
Brigham Young University
megan@byu.edu
Abstract

There are many mushroom supplements on the market claiming a variety of health benefits, and it is
difficult to discern which of these claims is backed by reliable research. Most of the existing research is conducted
using either human cells or animal models rather than human participants. Without being tested directly on
humans, this research has limited application. A review of the literature reveals a relatively small number of
studies have been conducted using human patients and those that do exist vary widely in study design and quality.
This article brings together all the existing studies that involve human participants for three popular
mushroom species that are commonly consumed as dietary supplements. The three species reviewed are Agaricus
blazei or royal sun agaric, Inonotus obliquus or chaga, and Ganoderma lucidum or reishi. Each study described
includes the study’s design, the condition being treated, the preparation, dosage, and duration of treatment, the
number of subjects, and a summary of the results.
The outcome of these studies is variable and caution is recommended when extrapolating the results.
Many factors, such as poor study design, small sample sizes, lack of replication, mushroom variability, and
problematic statistical methods, make it difficult to rely on the results of any individual study. Further research
using well designed clinical trials is needed to establish medicinal benefits for these three mushroom species.

Introduction

Mushrooms have long been used as medicine in cultures throughout the world. In recent years many
species have become popular dietary supplements to promote health. For some mushrooms, a great deal of
research on potential health benefits has been conducted, while for others there is very little scientific support. In
spite of this, countless mushroom supplements are available on the market with preparations, doses, and health
claims that vary widely between manufacturers.
It is difficult to determine if the consumption of various mushroom supplements provides health benefits.
Supplement companies often cite specific research to support their claims, but most of this has been conducted in
vitro or using animal models, usually mice and rats. While this information can suggest possible value, there are
differences in biochemical, physiological, and anatomical characteristics between animal models and humans.
Caution is needed when extrapolating the results of this research to supplements prepared for human use. The
number of studies of human subjects published in peer-reviewed literature is relatively small and variable (Leonard
2015).
This review draws together all of the human clinical trials found in the peer reviewed literature for three
popular mushroom supplements. Each of these three mushrooms species is consumed for medicinal purposes, is
widely obtainable, and is sold in dietary supplement form by multiple companies.
While the included trials provide a succinct view of the research that has been conducted thus far, they do
not indicate the reliability of the research. Many factors, such as study design, small sample sizes, lack of
replication, mushroom variability, problematic statistical methods and others, make it difficult to rely on the
outcomes of the research. This paper is not designed to evaluate each individual study or to substantiate or refute
the claims of any mushroom supplement companies, but rather to provide a view of the available research that
has been conducted on human subjects.

Methods

In this review, all the available human studies, including clinical, epidemiological, and case studies were
assessed. All of the studies were found by searching the mushroom’s genus and species in Web of Science (1945–
April 2015), BIOSIS (1980–April 2015), MEDLINE (up to April 2015), and clinicaltrials.gov (up to April 2015). Human
studies referenced in review articles found after 2005 were also considered. Included studies were limited to those
published in peer-reviewed journals and which involved at least ten subjects. Peer review status was determined
using Ulrichsweb (2015). The validity of the included publications was also assessed using Beall’s List of Predatory
Open Access Publishers (2015).
Studies where the intervention consisted of multiple ingredients, such as a combination of herbs and
mushrooms rather than a single mushroom species, were excluded. No restrictions were placed on date, language,
or study design. Where the article could not be read in its original form, the information was taken from a
translation, a review article, or from the article abstract. When applicable, this is noted within the respective
tables.
Many of the claims made by supplement companies and included in this review are not medical terms
and are taken directly from product labels or websites (Swanson Superior Herbs 2015; Myriad Mycology 2015;
Mushroom Wisdom 2015; Terrasoul 2015).
The information provided for each of the three species includes a description of the mushroom, its native
range, some of its uses in folk medicine, claims from supplement companies, a brief summary of in vitro and in vivo
animal research, and a table outlining the existing human studies. Each table includes the available information on
study design, preparation, dosage, subjects, duration, and a summary of the results.

Agaricus blazei (A. subrufescens, A. sylvaticus, A. rufotegulis or A. brasiliensis)
Common names:
almond portobello, royal sun agaricus, princess matsutake, royal agaricus, royal sun blazel, cogumelo do sol
(Brazil), himematsutake (Japan)

Figure 1. Agaricus blazei, commonly known as the almond portobello mushroom. Reprinted from Wikimedia Commons, by H. Krisp, n.d.,
accessed September 23, 2015, http://commons.wikimedia.org/wiki/File:Kleiner_Waldchampignon_Agaricus_
silvaticus.jpg#/media/File:Kleiner_Waldchampignon_Agaricus_silvaticus.jpg. Copyright 2013 CC BY-SA 3.0.

Agaricus blazei is commonly consumed for medicinal purposes in both Brazil and Japan (Xu, Beelman, and
Lambert 2012). Its flavor is characterized by an almond fragrance and a sweet taste. It is closely related to the
white button mushroom, Agaricus bisporus, regularly eaten in the United States (Kerrigan 2005). In the wild, A.
blazei is somewhat rare but has a wide distribution, growing throughout much the world. It has been assigned
several scientific names in different regions, A. subrufescens, A. sylvaticus, A. rufotegulis, or A. brasiliensis, but all
are now considered the same species (Kerrigan 2005).
In Brazil, A. blazei has historically been used to fight physical and emotional stress, to stimulate the
immune system, and to prevent or treat a variety of medical conditions such as diabetes, high cholesterol,
osteoporosis, peptic ulcers, digestive problems, and cancer (Firenzuoli, Gori, & Lombardo 2008). Today,
supplement companies advertise the benefits of A. blazei with claims that it “shows promise as anti-cancer and
anti-tumor medicine” and provides “cellular-level immune system support” (Myriad Mycology “blazei”; Swanson
Superior Herbs “blazei”).
A. blazei is one of the more commonly researched medicinal mushrooms. A large number of in vitro
studies have demonstrated a variety of effects including antitumor, antiviral, anti-inflammatory, antidiabetic, and
anti-allergic properties (Wang, Fu, & Han 2013). In vivo animal research has displayed its ability to improve the
efficacy of hepatitis B vaccines, stimulate immune response to leukemia, and promote T cell proliferation (Wang,
Fu, & Han 2013). A. blazei contains several immunostimulatory compounds such as β-1, 3-D-glucans, glucomannan,
and proteoglycans (El Enshasy & Hatti-Kaul 2013).
Like the other mushrooms in this review, relatively few human studies for A. blazei have been
documented in peer-reviewed journals. Table 1 lists those that meet the requirements for this review, 11 studies
in all. In addition to those in Table 1, five clinical trials can be found on clinicaltrials.gov. The earliest began in 2005
and the latest in 2011. These trials tested the effects of A. blazei on patients with hepatitis C, multiple myeloma,
inflammatory bowel disease, and type 2 diabetes mellitus. The results of two of the five trials can be found in Table
1 (Tangen et al. 2015; Hsu et al. 2007). The results of two were not located in the literature search, and the fifth
trial exploring the effect of A. blazei treatment on inflammatory bowel disease is listed as currently recruiting
patients (clinicaltrials.gov 2015).

Table 1 – Clinical Human Studies for A. blazei
Citation

Condition
Treated

Study Design

Preparation

Dose

Subjects

Length

Results

Ahn et al.
2004

cancer;
various

randomized,
blinded, placebocontrolled
preliminary trial

A. blazei Murill extract
1 packet = 1800 mg
(Kyowa Engineering Co.,
Tokyo, Japan)

3 packs/day
(5400 mg/day)

100 cancer patients
with either cervical,
ovarian, or endometrial
cancer treated with
chemotherapy;
treatment (n = 39);
control (n = 61)

9 wks

Safety, Subjective and Physiological Effects: Natural killer cell
activity in treated patients was significantly higher than nontreated patients. Fewer chemotherapy-associated side effects
(such as lack of appetite, alopecia areata, general weakness)
were reported in treated patients.

Figueira
et al.
2014

HIV

clinical trial (no
randomization,
blinding, or
placebo-control)

A. brasiliensis syrup
formulation (Cogumelo
do Sol Agaricus do Brasil
LTDA, Brazil)

30 mg/kg of
body
weight/day

24 children (2–8 yrs
old);
HIV positive children
received treatment (n =
10), compared with HIV
negative children used as
control (n = 14)

3 mos

Physiological Effects: After supplementation, a reduction of
thiobarbituric acid-reactive substances and nitrite and nitrate
values and an increase in diphenyl-picrilhidrazil and Trolox
equivalent antioxidant capacity values were observed in HIVpositive subjects. These results suggest that A. brasiliensis has
potential as a complimentary treatment for HIV positive
children.

Fortes et
al. 2009

colorectal
cancer

randomized,
placebocontrolled, clinical
trial

A. sylvaticus

30 mg/kg of
body
weight/day

56 patients with
colorectal cancer
(stages I, II, and III);
treatment (n=28),
control (n=28)

6 mos

Physiological Effects: Treated patients had significantly better
results for hematological and immunological parameters and
lower glycemia levels than the placebo group.

Hsu et al.
2007

type 2
diabetes

randomized,
double-blind,
placebo-controlled
clinical trial

A. blazei Murill extracted
from dried fungal bodies,
1 capsule = 500 mg (Eng
Chiao BioTechnology Co. Ltd.,
Taiwan)

3 capsules/day
(1500 mg/day)

60 patients with type 2
diabetes; treatment (n =
29), control (n = 31)

12 wks

Physiological Effects: The treatment group showed significantly
lower insulin concentrations, and scored lower on the
homeostasis model assessment for insulin resistance index. The
plasma adiponectin concentration increased significantly in the
treatment group but decreased among those taking the placebo.
Insulin resistance improved among treated subjects with type 2
diabetes when compared with the placebo group.

Inuzuka
2002
(from
abstract)

hepatitis C

clinical trial (no
randomization,
blinding, or
placebo-control)

A. blazei condensed
liquid, ABCL (Agaricus
Mushroom Extract)

ABCL orally
2 times/day
(quantity
undetermined)

20 patients with chronic
hepatitis C

12 wks

Safety and Physiological Effects: A decreasing effect for serum γGTP activity was found in 80% of the patients, suggesting ABCL
may be useful for patients with light hepatopathy such as C-type
hepatitis. No toxicological findings or other side effects were
observed.

Lima et
al. 2012

age

randomized,
double-blind,
placebo-controlled
clinical trial

Gelatin capsules
containing 300 mg A.
blazei Murill dry extract
were obtained from
Estância Valemar (São
Paulo, Brazil)

3 capsules/day
(900 mg/day)

57 females; treatment
(n = 28), control (n = 29)

60 days

Physiological Effects: Body mass index, abdominal girth, body
composition, blood pressure, and cytokine levels were
measured. No changes from baseline were detectable for any
parameter in either the treatment or placebo groups.

Liu et al.
2008

safety and
immunemodulating
activity

clinical trial (no
randomization,
blinding, or
placebo-control)

A. brasiliensis; dried
fruiting bodies, strain
KA21, cultivated outdoors
in Brazil, 1 tablet = 300
mg

group 1:
10 tablets,
3 times/day
(9000mg/day);
group 2:
5 tablets,
2 times/day
(3000mg/day)

23 healthy subjects
taking no medication;
group 1 (n = 11), group 2
(n = 12)

group 1:
6 mos;
group 2:
3 mos

Physiological Effects: Group 1 was given a high dose and assessed for
changes in liver function, renal function, and nutritional conditions. No
statistically significant difference before and after administration, and
no side effects caused by long-term administration were observed.
Group 2 was measured for body weight, BMI, percentage body fat,
percentage of visceral fat, blood cholesterol, neutral fat, and blood
glucose and natural killer cell activity. There were statistically
significant decreases in all of the indices after treatment, except
natural killer cell activity, which increased. This suggests that the A.
brasiliensis fruiting body may provide general health benefits.

Senseiro, A. blazei Murill
granulated powder;
1 packet = 1800 mg
(Kyowa Wellness Co.,
Ltd., Tokyo, Japan)

group 1:
1 pack/day;
group 2:
2 packs/day;
group 3:
3 packs/day

78 cancer survivors;
group 1 (n = 30), group
2 (n = 24), group 3 (n =
24)

6 mos

Safety: This trial was designed to assess the safety of Senseiro.
The treatment did not cause problems in most patients at the
dosages tested. Only 9 patients reported adverse effects, most
were digestive in nature such as nausea and diarrhea, and 1
patient developed a liver dysfunction–related food allergy.

Ohno et
al. 2011

cancer;
various

phase I clinical trial
(no randomization,
blinding, or
placebo-control)

(A third treatment
group was also included
in the study but not
included this review
because there were
fewer than 10 subjects.)

Ohno et
al. 2013

cancer
remission

preliminary,
longitudinal, open,
clinical trial (no
randomization,
blinding, or
placebo-control)

Senseiro, A. blazei Murill
granulated powder;
1 packet = 1800 mg
(Kyowa Wellness Co.,
Ltd., Tokyo, Japan)

group 1:
1 pack/day;
group 2:
2 packs/day;
group 3:
3 packs/day

67 cancer patients;
group 1 (n = 23), group
2 (n = 22), group 3: (n =
22)

6 mos

Subjective Effects: A before and after questionnaire was used to
evaluate quality of life (QOL) among patients. The results
showed a statistically significant improvement in QOL in both
physical and mental components. Males improved more in
physical components, while females improved only mental
components. Ages 65 and under improved mental components,
while ages 66 and older improved physical components. Optimal
dose effects occurred at 2 packs/day.

Tangen
et al.
2015

multiple
myeloma

randomized,
double-blind,
placebo-controlled
clinical trial

AndoSan extract,
containing 82% of A.
blazei Murill

60 ml/day

40 patients with multiple
myeloma, treatment (n =
19), control (n = 21)

7 wks
(approx.)

Physiological Effects: No statistically significant clinical impact of
AndoSan was detected.

Yoshimur
a et al.
2010

prostate
cancer

open-label clinical
trial (no
randomization,
blinding, or
placebo-control)

Senseiro, A. blazei Murill
granulated powder;
1 packet = 1800 mg
(Kyowa Wellness Co.,
Ltd., Tokyo, Japan)

3 packs/day
(5400 mg/day)

32 prostate cancer
patients following
radical prostatectomy

6 mos

Safety and Physiological Effects: There was no response in terms
of prostate-specific antigen. No statistically significant anticancer
activity and no serious adverse effects were observed.

Inonotus obliquus (Fungus betulinus)
Common Names:
Chaga (Russia), birch fungus, white rot fungus, kabanoanatake (Japan)

Figure 2. Inonotus obliquus, commonly known as birch fungus. Reprinted from Wikimedia Commons, by H. Baker, n.d., accessed September 23,
2015, http://commons.wikimedia.org/wiki/File:Inonotus_obliquus_141813.jpg#/media/File:Inonotus_obliquus_141813.jpg. Copyright 2011 CC
BY-SA 3.0.

Inonotus obliquus is a polypore mushroom that grows as a plant pathogen on the trunk of birch trees in
northern latitudes throughout the world (El Enshasy & Hatti-Kaul 2013). According to systematic classification
methods, I. obliquus is also known as birch fungus, Fungus betulinus. I. obliquus can only be collected from living or
freshly cut, mature birch trees. On dry standing or fallen trees, the mushroom dies, and the content of active
compounds decreases dramatically (Shashkina, Shashkin, & Sergeev 2006).
The Tartars of West Siberia traditionally used I. obliquus to treat “tuberculosis, gastrosia, liver diseases,
heart diseases, and ascariasis” (Zhong et al. 2013). It is currently used to treat various disorders including
gastrointestinal cancer, as well as cardiovascular disease and diabetes in Russia, Poland, and most of the Baltic
countries (Zhong et al. 2013). Supplement companies that sell I. obliquus in the United States claim that it has
demonstrated “a variety of beneficial cardiovascular actions and immune supporting benefits” and that it is
“currently being used in numerous cancer studies” and “being studied for its ability to treat the virus HIV”
(Mushroom Wisdom “chaga”; Myriad Mycology “chaga”).

I. obliquus has a high content of compounds such as β-glucans which may affect the immune system, (El
Enshasy & Hatti-Kaul 2013) and secondary metabolites, including phenolic compounds, melanins, and lanostanetype triterpenoids (Zhong et al. 2013).
Despite the small number of human studies, in vitro and in vivo animal studies have been extensive. I.
obliquus has exhibited anticancer activity in various types of tumor cells. In vitro studies have demonstrated
antiviral effects, platelet aggregation inhibitory activities, and anti-inflammatory and analgesic properties (Zhong
et al. 2013). In vivo, antitumor activity, antioxidant activity, and an increase in hypoglycemic activity have all been
demonstrated in mice (Zhong et al. 2013).
Although there is widespread use in Russia (Zhong et al. 2013), only two human studies were found in the peer
reviewed literature, and both are over 30 years old as seen in Table 2. No controlled studies designed to assess the
safety of I. obliquus were found and no studies were reported on clinicaltrials.gov (2015). Like many mushroom
supplements, most of the evidence for safety and efficacy appear to be based on I. obliquus's long traditional use.
Table 2 – Clinical Human Studies for I. obliquus
Citation

Condition
Treated

Study Design

Preparation

Dose

Subjects

Length

Results

Dosychev
& Bystrova
1973

psoriasis

clinical trial (not
randomized,
controlled, or
blinded)

Befungin® (contains an
EtOH (10%) extract of Chaga
with 1.76% of cobalt
chloride or 2.0% cobalt
sulfate and is manufactured
in 8 factories in Russia) and
Chaga Extract.

1 tablespoon,
3 times/day,
20–30 minutes
before meals

50 patients with
psoriasis;
group 1: (n =
24);
group 2: (n =
18);
group 3: (n = 8)

group 1: 3–6
mos;
group 2: ≤12
mos;
group 3: >2 yrs

Outcome of Treatment: Complete disappearance of
psoriatic eruptions were observed in 38 patients and
considerable improvement in 8 patients. No therapeutic
effect was achieved in 4 patients. Gastrointestinal tract
symptoms were modified or disappeared completely. A
less significant effect was observed in patients with
diseases of the ears, nose, and throat, those abusing
alcohol, and those having significant long-term nutrition
disorders.

Fedotov &
Yu 1981
(article in
Russian)

peptic ulcers

clinical trial (not
randomized,
controlled, or
blinded)

Befungin® (currently
manufactured by
Tathimfarmpreparati,
Russia)

group 1:
4.5 ml/day;
group 2:
45 ml/day;
group 3:
90 ml/day

58 patients with
peptic ulcers

24 days, results
assessed for an
additional 2 wks

Subjective Effects and Outcome of Treatment: The
therapeutic effect of Befungin was connected with a
decrease in pain caused by peptic ulcers. The effect
increased with higher doses. After treatment ceased,
pain returned to normal levels.

Ganoderma lucidum
Common Names:
reishi (Japan), ling-zhi (China), spirit plant, mushroom of immortality

Figure 3. Ganoderma lucidum, commonly known as spirit plant. Reprinted from Wikimedia Commons, by E. Steinert, n.d., accessed September
23, 2015, http://commons.wikimedia.org/wiki/File:Ganoderma_lucidum_02.jpg. Copyright 2005 CC BY-SA 2.5-2.0-1.0.

Ganoderma lucidum can be found growing on plum trees throughout Asia and in other parts of the world.
It has a long history of use in Japanese and Chinese traditional medicine to “increase energy, stimulate the immune

system, and promote health and longevity” (Chang & Buswell 1999). Modern uses of G. lucidum include treatment
for coronary heart disease, arteriosclerosis, hepatitis, arthritis, nephritis, bronchitis, hypertension, cancer, and
gastric ulcers (Boh 2007). Claims from supplement companies include its use in treating “insomnia, allergies, liver
disease, anxiety, rheumatoid arthritis, and various forms of cancer” as well as its ability to “build resistance to
illness, detox the body, and calm the nerves” (Myriad Mycology “reishi”; Terrasoul “reishi”).
Not only is G. lucidum one of the most frequently consumed dietary supplements, it is one of the most
well-researched mushrooms. A wide range of in vitro and in vivo animal studies have been conducted to
investigate the various health benefits of G. lucidum. These have provided evidence to suggest it has the potential
to reduce the immunosuppressive response induced by anticancer drugs and abate autoimmune diseases. G.
lucidum has also demonstrated anti-inflammatory, antidiabetic, antiviral, and antibacterial activity both in vivo and
in vitro (Boh et al. 2013). This mushroom contains more than 50 types of polysaccharides and peptidepolysaccharides complexes in addition to about 120 bioactive compounds (El Enshasy & Hatti-Kaul 2013).
Many of the clinical trials for G. lucidum were designed to test its adjuvant use in cancer therapy although
a variety of other conditions have also been studied Twenty-six studies met the requirements of this review and
are included in Table 3. Four additional trials involving the treatment of Parkinson’s disease, rheumatoid arthritis,
and pediatric cancer were found on clinicaltrials.gov. One of these trials was not located in the literature search
and two did not meet the review criteria (Shing et al. 2008; Li et al. 2007). The fourth trial looking at the effect of
G. lucidum on patients with head and neck cancer is currently recruiting patients (clinicaltrials.gov 2015).
Table 3 – Clinical Human Studies for G. lucidum
Citation

Condition
Treated

Study Design

Preparation

Dose

Subjects

Length

Results

Chen et al.
2006

advanced
colorectal
cancer

open-label
clinical trial (no
randomization,
blinding, or
placebocontrol)

Ganopoly, 1 capsule =
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co., Auckland, NZ)

5.4 g/day

41 patients with
advanced colorectal
cancer

12 wks

Physiological Effects: When compared to pre-treatment levels, no
statistically significant improvement was observed for the
following indices: Lymphocyte mitogenic reactivity to
phytohemagglutinin, T lymphocytes counts for the surface
molecules CD3, CD4, CD8 and CD56, and natural killer cell activity.

Chu et al. 2012

hypertension

randomized,
placebocontrolled
crossover
clinical trial

G. lucidum
polysaccharide extract
capsules;
360 mg/capsule =
13.2 g fresh mushroom

2 capsules,
2 times/day
(1440
mg/day)

26 patients with
borderline elevations
of blood pressure
and/or cholesterol

12 wks;
placebo
and
crossover
switch at
4 wks

Physiological Effects: Plasma insulin and homeostasis model
assessment-insulin resistance were lower in the treatment group
than in the placebo group..

Fu & Wang
1982

atrophic
myotonia

preliminary,
open label
study (no
randomization
, blinding, or
placebocontrol)

Ganoderma, an
injection of a water
soluble preparation of
G. lucidum spores
(Institute of Materia
Medica)

400 mg/day

10 patients with
atrophic myotonia

unspecifi
ed, at
least 2
wks;
patients
were
followed
after
treatmen
t for an
average
of 5.2 yrs

Safety and Subjective Effects: Sleep, appetite, and physical
strength improved among the patients after 2 weeks. Five
reported marked improvement, 2 reported improvement, and 3
reported slight improvement in muscle strength with mytonic
symptoms relieved. Six patients displayed at least some long-term
results.

Gao et al.
2004a

type 2
diabetes
mellitus

phase I/II
randomized
controlled,
multicenter
clinical trial (no
blinding)

Ganopoly, 1 capsule=
600 mg extract = 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

71 patients with type
2 diabetes mellitus;
treatment (n = 35);
control (n = 36)

12 wks

Safety and Physiological Effects: A statistically significant decrease
in glycosylated hemoglobin was observed in the treated group in
comparison with the control group. The results suggest that
Ganopoly is efficacious and safe in lowering blood glucose
concentrations.

Gao et al.
2004b

coronary
heart disease

phase I/II
randomized,
placebocontrolled
clinical trial

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

170 patients with
coronary heart
disease;
treatment (n = 88);
control (n = 82)

12 wks

Safety and Physiological Effects: Treatment improved primary
symptoms, decreased abnormal electrocardiogram appearance,
and decreased blood pressure and cholesterol in comparison to
the control group.

Gao et al.
2002a

chronic
hepatitis B

phase I/II
randomized,
placebocontrolled
clinical trial

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

78 patients with
chronic hepatitis B;
treatment (n = 52);
control (n = 26)

12 wks
treatmen
t and 12
wks
follow-up

Safety and Physiological Effects: A decreased level of hepatitis B
virus DNA and hepatitis B e-antigens occurred in 25% of the
treatment group vs. 4% of the control group. The number of
treated patients with normal aminotransferase values was 33%
and 13% had cleared hepatitis B surface antigens vs. 0% of control
patients. Results indicate that Ganopoly is well tolerated and
appears to be active against HBV in patients with chronic hepatitis
B.

Gao et al.
2003a

lung cancer

randomized,
double-blind,
placebocontrolled,
multicenter
clinical trial

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

68 patients with stage
III or IV lung cancer;
treatment (n = 37);
control (n = 31)

12 wks

Safety, Subjective and Physiological Effects: The number of treated
patients with stabilized cancer at 12 weeks was 35.1% vs. 22.6% of
control patients. Treatment resulted in a statistically significant
increase in Karnofsky performance scores (a method of measuring
patients' performance of daily living activities) in 50% vs. 14.3% in the
control group. Immune responses were significantly increased in
treated patients but not control patients.

Gao et al.
2002b

advanced
cancer;
various

phase I/II
open-label
clinical trial
(no
randomization
, blinding, or
placebocontrol)

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

143 patients with
advanced, previously
treated cancer

12 wks

Safety and Physiological Effects: There were 32 patients in stable
condition for at least 12 weeks. Of these, there was a statistically
significant increase in lymphocyte myogenic reactivity and natural
killer cell activity. Ganopoly may have an adjunct role in the
treatment of patients with advanced cancer.

Gao et al.
2003b

advanced
cancer;
various

Pre-post study
case series (no
randomization,
blinding, or
placebocontrol)

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

34 patients with
advanced stage
cancer (lung, breast,
brain, liver, colon,
prostate, bladder)

12 wks

Physiological Effects: Compared to baseline, a statistically
significant increase in T cell populations and natural killer cell
activity was measured at 12 weeks.

Gao et al.
2005a

lung cancer

open-label
clinical trial (no
randomization,
blinding, or
placebocontrol)

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

30 lung cancer
patients

12 wks

Physiological Effects: No statistically significant improvement was
observed for the following indices: Lymphocyte mitogenic reactivity to
phytohemagglutinin, T lymphocytes counts for the surface molecules
CD3, CD4, CD8 and CD56, the mean plasma concentrations of
interleukin (IL)-2, IL-6, and interferon (IFN), and natural killer cell
activity.

Gao et al.
2005b

neurasthenia

randomized,
double-blind,
placebocontrolled
parallel study

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

123 patients with
neurasthenia
according; treatment
(n = 62);
control (n = 61)

8 wks

Safety, Subjective and Physiological Effects: Ganopoly was well
tolerated in the study patients and there were statistically
significant improvements in the CGI severity, sense of fatigue, and
sense of well-being (symptoms in neurasthenia) scores in the
treatment group compared with the control.

Gao, et al.
2005c

colorectal
cancer

clinical trial
(no
randomization
, blinding, or
placebocontrol)

Ganopoly, 1 capsule=
600 mg extract
equivalent to 9 g of
fruiting body (provided
by Encore International
Co. Auckland, NZ)

3 capsules,
3 times/day
before meals
(5400
mg/day)

47 patients with
advanced colorectal
cancer

12 wks

Physiological Effects: No statistical significance was observed in
mitogenic reactivity to phytohemagglutinin when a compared to
baseline values and those after 12-weeks of treatment.

Jin et al. 1996

hypertension

randomized,
double-blind,
placebocontrolled
clinical trial

G. lucidum extract
tablets, each 55mg =
1.375g of sporophores
(Wakan Shoyaku
Botany Institute)

2 tablets
orally,
3 times/day
(330 mg/day)

54 patients with stage
II hypertension;
treatment (n = 40);
control (n = 14)

4 wks

Physiological Effects: The treatment group had a statistically
significant drop in systolic and diastolic blood pressure plus a
statistically significant change in nail fold microcirculation
compared to the control group. Improvements in capillary loop
density, diameter, and red blood cell velocity were also observed.
The results indicate G. lucidum may contribute to prevention and
reversion of target organ deterioration in hypertension.

Kanmatsuse
1985 (article
in Japanese)

hypertension

clinical trial (no
randomization,
blinding, or
placebocontrol)

lyophilized G.lucidum
extract tablets (240 mg)

6 tablets/day
(1440
mg/day)

53 patients with
essential, mild or no
hypertension;
group 1: essential
hypertension;
group 2: mild–no
hypertension

6 mos

Physiological Effects and Outcome of Treatment: G. lucidum had a
statistically significant blood-pressure lowering effect on group 1
patients with essential hypertension, but no effect on group 2
patients with essential or borderline hypertension.

Kwok et al.
2005

hemostasis

prospective,
randomized,
double-blind
placebocontrolled
clinical trial

G. lucidum capsules
containing 500 mg
active extract.
(Greenvalley® Ltd.,
Shanghai, China)

1 capsule,
3 times/day
(1500
mg/day)

40 healthy volunteers;
treatment (n = 20);
control (n = 20)

4 wks
treatmen
t and 4
wks
follow-up

Safety: G. lucidum was not associated with gross impairment of
platelet and global hemostatic function and did not increase the
risk of bleeding in healthy individuals.

Noguchi et al.
2008a

lower urinary
tract
symptoms

randomized,
double-blind,
placebocontrolled,
dose-ranging
clinical trial

G. lucidum tablets
(Chlorella Industry
Tokyo, Japan)

group1:
0.6 mg/day;
group 2:
6 mg/day;
group 3:
60 mg/day

50 men with lower
urinary tract
symptoms;
group 1: (n = 12);
group 2: (n = 12);
group 3: (n = 14);
control: (n = 12)

8 wks

Safety and Physiological Effects: There were no statistically significant
differences in baseline characteristics for age, PSA level, prostate
volume, peak urinary flow rate, or symptom score among the
treatment groups vs. control; however, the treatment groups
receiving 6 mg and 60 mg had significantly improved International
Prostate Symptom Scores. No major adverse effects were observed.

Noguchi et al.
2008b

lower urinary
tract
symptoms

randomized,
double-blind,
placebocontrolled
clinical trial

G. lucidum tablets
(Chlorella Industry
Tokyo, Japan)

6 mg/day

88 men with lower
urinary tract
symptoms;
treatment (n = 44);
control (n = 44)

12 wks

Safety and Physiological Effects: There was a statistically
significant improvement in the International Prostate Symptom
Score in the treatment group vs. control. Overall treatment was
well tolerated with no severe adverse effects.

Oka et al. 2010

colorectal
adenomas

concurrent
clinical trial (no
randomization,
blinding, or
placebocontrol)

G. lucidum watersoluble extract of
mycelia (MAK
Wakunaga
Pharmaceutical Co.,
Ltd.)

3 capsules,
2 times/day
(1500
mg/day)

96 patients with
colorectal adenomas;
treatment (n = 96);
control (n = 102)

12 mos

Physiological Effects and Outcome of Treatment: The number and
size of adenomas significantly decreased in the treatment group
and increased in the control group.

Wachtel-Galor
et al. 2004a

antioxidant
capacity

randomized,
doubleblinded,
placebocontrolled,
crossover trial

G. lucidum capsules
1440 mg equivalent to
13.2 g of fresh
mushroom (Vitagreen
Co Ltd Hong Kong)

4
capsules/day
(1440
mg/day)

18 healthy adults

4 wks

Physiological Effects: No statistically significant change in antioxidant
status, coronary heart disease risk, DNA damage, immune status,
inflammation, or markers of liver and renal toxicity were found.

WachtelGalor,
Tomlinson, &
Benzie 2004b

antioxidant
capacity

randomized,
doubleblinded,
placebocontrolled,
crossover trial

G. lucidum capsules
720 mg equivalent of
6600 mg of fresh
mushroom (Vitagreen
Co Ltd Hong Kong)

2
capsules/day
(720 mg/day)

10 healthy volunteers

10 days

Safety and Physiological Effects: There was no statistically
significant difference in a-tocopherol concentrations, urine
antioxidant capacity, fasting plasma ascorbic acid, erythrocyte
superoxide dismutase and glutathione peroxidase activities,
plasma lipids, or uric acid during the treatment period. There was
an increase in acute plasma antioxidant capacity. No deleterious
effects were measured. Results indicate that G. lucidum is safe for
healthy adults.

Wang et al.
2008 (article in
Chinese.
Information
taken from
systematic
review; Klupp
et al. 2014)

type 2
diabetes

randomized,
placebocontrolled trial

G. lucidum, the raw
mushroom was made
into powder through
decoction,
concentration, drying,
and then into capsules.
(Guo-Ren-Shun-TianTang Pharmaceutical
Company)

1000 mg,
3 times/day
(3000
mg/day)

50 outpatients with
type 2 diabetes;
(unable to determine
treatment number)

12 wks

Physiological Effects: Results for post-prandial glucose levels after
treatment were mixed. At 2 hours there was a statistically
significant reduction for those taking placebo compared to the
treatment group. However, at 4 hours, the treatment group
displayed a statistically significant drop when compared to the
control. According to the systematic review (Klupp et al. 2014), the
evidence in this study did not support the use of G. lucidum for
treatment of type 2 diabetes.

Wicks et al.
2007

safety and
tolerability

randomized,
doubleblinded,
placebocontrolled
phase I clinical
trial

SunRecome, G. lucidum
extract 500 mg capsules
(Xi’an Green Valley
Pharmaceutical Co.,
China)

4 capsules,
2 times/day
(4000
mg/day)

16 healthy patients;
treatment (n = 8);
control (n = 8)

10 days

Safety: No adverse effects were observed in the treatment group
following intake.

Xiao, Liu, &
Chen 2003

mushroom
poisoning

clinical trial (no
randomization,
blinding, or
placebocontrol)

G. lucidum, 1000 mg
decocted with water to
600 ml

Single dose
(taken in
conjunction
with
conventional
treatment)

14 patients suffering
from poisoning by
Russula subnigricans
compared to 11
patients treated with
conventional treatment
alone.

assessed
after
single
dose

Physiological Effects: Decreased urinary protein and red blood cell
count as well as other improved markers of kidney injury were
observed in the treated group.

Yoshimura et
al. 2010

prostate
cancer

open-label
clinical trial (no
randomization,
blinding, or
placebocontrol)

Rokkaku Reishi
(Suntory Holdings,
Osaka, Japan)
(quantity
undetermined)

3 packs/day

15 prostate cancer
patients following
radical prostatectomy

6 mos

Safety and Physiological Effects: There was no response in terms
of prostate-specific antigen. No statistically significant anticancer
activity and no serious adverse effects were observed.

Zhang et al.
2008

T
lymphocyte
levels in
athletes

randomized,
double-blind,
placebocontrolled
clinical trial

G. lucidum capsules
(Shanghai Green-Valley
Co., China)
(quantity
undetermined)

Control and
group 1:
placebo;
group 2:
10
capsules/day;
group 3:
20
capsules/day

40 male football
players assigned to
four groups: control,
group 1, group 2,
group 3. The three
treatment groups
stayed in normobaric
hypoxic rooms for 28
days. All four groups
trained together at
sea level.

6 wks

Physiological Effects: There were no statistically significant
differences and changes in T lymphocyte subsets between groups
1 and 2, but in group 3 the percentage of T lymphocytes surface
molecules CD3+ and CD4+ increased significantly. This suggests
that the ingestion of G. lucidum at levels of 20 capsules a day
could have a beneficial effect on T lymphocyte levels in elevation
training.

Zhao et al.
2012

fatigue in
breast
cancer
patients

pilot,
randomized,
placebocontrolled
clinical trial

G. lucidum spore
powder 1000 mg
(Beijing Great Wall
Pharmaceutical
Factory, Batch number
B20050008)

1000 mg,
3 times/day
(3000
mg/day)

48 breast cancer
patients with cancerrelated fatigue;
treatment (n = 25);
control (n = 23)

4 wks

Safety and Subjective Effects: The treatment group reported
statistically significant improvements in physical well-being and
fatigue after intervention. They also reported less anxiety and
depression and better quality of life. No serious adverse effects
occurred during the study.

Discussion

While there is value in combining the available clinical trials for these three mushroom species, it is
important to address the difficulties involved in evaluating this kind of research. Many factors make it challenging
to ascertain the health benefits of mushroom supplements.
First, there are a number of different purposes for conducting clinical trials. Some of the studies included
in this review were designed to assess the safety and side effects of mushroom consumption. Others measured
specific physiological effects such as natural killer cells activity or plasma insulin levels (Ahn et al. 2004; Chu et al.
2012). Several used patient reporting methods to measure subjective effects such as pain or quality of life (Fu &
Wang 1982; Zhao et al. 2012). A small number were designed to measure the outcome of treatment for a specific
disease (Oka et al. 2010; Dosychev & Bystrova 1973). Each of these end results provides useful information for
further research, but none are designed to provide conclusive evidence.
For example, phase I clinical trials, sometimes called preliminary or pilot studies, like Zhao et al. (2013) or
Ohno et al. (2011), are generally designed to evaluate a treatment’s safety, establish a dosage range, and identify
side effects (clinicaltrials.gov 2015). This information is used to determine if further research can safely be
conducted. Twelve of the 39 clinical trials included in this review were specifically designated as phase I, pilot, or
preliminary trials, although at least five others reported information on safety and side effects.
Variations in study design also affect how results are evaluated. Open label studies, such as Yoshimura et
al. (2010), are structured so that both the patients and investigators are aware of the treatment the patient is
receiving (clinicaltrials.gov 2015). These studies do not control for human bias so while they may indicate the
potential benefit for further research, they don’t provide stand-alone evidence. Double-blinded studies, where
neither the patients nor the investigator know if the patient is receiving the test substance or a placebo, are
needed to support the results. Only 13 of the 39 trials in this review were double-blinded.
Other design characteristics, such randomization and placebo controls, are needed to achieve reliable
results. Both were present in only 21 of the included studies. Sample sizes also impact the evaluations of results.
Small sample sizes make it difficult to determine the likelihood that the results are statistically significant. This
commonly produces publications with falsely positive results (Reinhart 2015, pp.23–28). Only four of the studies in
this review had sample sizes with 100 or more patients.
Another challenge that arises while evaluating a body of research is the strong incentive among
researchers to publish studies with positive results. Because there is no general standardization for data analysis in
clinical trials, it is common for researchers to choose those statistical methods that provide a statistically significant

outcome. While this is not necessarily intentional, it does tend to produce results that appear more favorable to a
researcher’s hypothesis than the data may warrant (Reinhart 2015, pp.4–5).
Conversely, there is often an inability or lack of incentive to publish negative results. Journals looking for
impactful research may be less likely to publish a study that shows no measurable benefit for mushroom
consumption (Reinhart 2015, pp.24–25). Researchers also may abandon a study that shows no effect in pursuit of
other, more promising, research. Or, they may measure a number of indices during treatment, but choose to
publish only those indices that show statistical significance. As a result, the body of available research is generally
skewed toward studies that show a positive effect. There were 36 trials in this review that measured indices
beyond side effects; 25 of these reported positive effects with treatment. Of those completed studies that were
reported on clinicaltrials.gov, three of seven were not found during the literature search. While the reason these
three trials were not published was not determined, it does call into question the cause for a lack of publication or
for further research on the topic.
There is, in fact, a noteworthy lack of follow-up research among all of the included trials. Only three
authors appear to have conducted further research (Wachtel-Galor et al. 2004b; Noguchi et al. 2008b; Gao et al.
2003b; 2005a). It would seem likely that promising results would elicit further study and the absence of further
research raises some doubt about the ability to replicate positive results.
Another concern is the source of motivation for the research. It is not always easy to determine if
research is funded in whole or in part by organizations with an incentive to find positive results. Because many of
the included studies are testing the effectiveness of a specific brand of dietary supplement, such as Ganopoly or
Senseiro, it is possible that there is an incentive to establish evidence for the health benefits of these products
(Gao et al. 2002a; Ohno et al. 2013). This lack of objectivity can have an effect on the validity of even well-designed
research (Jagsi et al. 2009).
Where reliable research methods are used, mushrooms produced as dietary supplements still lack
standards for cultivation and preparation, as well as testing protocols needed to guarantee product quality
(Sullivan, Smith, & Rowan 2006). The bioactivity of mushrooms can vary widely depending on the strain, growing
conditions, developmental stages, and the parts of the mushroom that are consumed (Borchers et al. 2008).
Extraction methods such as water temperature or ethanol concentration can also impact the bioactivity of the
resulting product (Borchers et al. 2008). Even when these variables are carefully recorded and disclosed, the study
results for a particular treatment cannot always be extrapolated to the general consumption of a mushroom
species.
Finally, there are few regulations for dietary supplements that are sold in the United States. Clinical
studies are not a requirement and the active ingredients of many commercial mushroom products are not known.
As a result, adulteration with other species is common (Wasser 2011). This provides another challenge to both
consumers and health professionals when determining the effectiveness and safety of consuming these products.
The human trials included in this review vary greatly with regard to study design, preparation, dosage, and
number of subjects, as well as the analysis and reporting of results. While many show interesting possibilities for
the use of these three mushroom species in treating a variety of medical conditions, additional research using welldesigned clinical studies and reliable statistical methods is still needed. Further double-blinded, placebo-controlled
studies with large trial populations and well standardized preparations are necessary to reliably establish the
efficacy of these mushrooms as dietary supplements.
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